# Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02249338** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 53 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BIIL 284 BS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02249338
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 2000-04
- **Final completion:** —
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249338, "Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02249338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*